SG11201807785VA - Neuroactive steroids, compositions, and uses thereof - Google Patents
Neuroactive steroids, compositions, and uses thereofInfo
- Publication number
- SG11201807785VA SG11201807785VA SG11201807785VA SG11201807785VA SG11201807785VA SG 11201807785V A SG11201807785V A SG 11201807785VA SG 11201807785V A SG11201807785V A SG 11201807785VA SG 11201807785V A SG11201807785V A SG 11201807785VA SG 11201807785V A SG11201807785V A SG 11201807785VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- applicant
- tremor
- pct
- rule
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 2
- 206010044565 Tremor Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000006517 essential tremor Diseases 0.000 abstract 2
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 abstract 1
- -1 alphadalone Chemical compound 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950007402 eltanolone Drugs 0.000 abstract 1
- 229950006567 ganaxolone Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000002020 sage Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
Abstract
Extrasynapticx(336 1250 0 Compound 9 1000 Diazepam '47; 750 4- , 0 500 2 0 0.01 Concentration (PM) FIG. 1A W O 20 17 / 15 6 103 Al 1 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/156103 Al 14 September 2017 (14.09.2017) WIPO I PCT (51) International Patent Classification: (72) Inventor; and A61K 31/57 (2006.01) A61K 31/575 (2006.01) (71) Applicant : COLQUHOUN, Helen [US/US]; 23 Regis A61K 31/56 (2006.01) A61K 31/58 (2006.01) Road, Arlington, MA 02474 (US). 111111111111110111011111111111010111110 0111111111111101011111011111111111110111111 (21) International Application Number: PCT/US2017/021325 (22) International Filing Date: 8 March 2017 (08.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/305,279 8 March 2016 (08.03.2016) US 62/355,174 27 June 2016 (27.06.2016) US 62/355,669 28 June 2016 (28.06.2016) US 62/360,762 11 July 2016 (11.07.2016) US 62/360,758 11 July 2016 (11.07.2016) US (71) Applicant: SAGE THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventor: KANES, Stephen, Jay; 125 Guernsey Rd, Swartmore, PA 19081 (US). (74) Agent: MCCARTY, Catherine, M.; LANDO & ANA- STASI, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [Continued on next page] (54) Title: NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF (57) : Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depres- sion, e.g., postpostum depression; and anxiety disorder, the method compris- ing administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety dis- order with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopreg- nanolone, alphadalone, ganaxolone, or alphaxolone). WO 2017/156103 Al MIDEDIMOMOIDEIRMEMOMOHIMOMMIUMEMOIS (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3))
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662305279P | 2016-03-08 | 2016-03-08 | |
US201662355174P | 2016-06-27 | 2016-06-27 | |
US201662355669P | 2016-06-28 | 2016-06-28 | |
US201662360762P | 2016-07-11 | 2016-07-11 | |
US201662360758P | 2016-07-11 | 2016-07-11 | |
PCT/US2017/021325 WO2017156103A1 (en) | 2016-03-08 | 2017-03-08 | Neuroactive steroids, compositions, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807785VA true SG11201807785VA (en) | 2018-10-30 |
Family
ID=59789807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807785VA SG11201807785VA (en) | 2016-03-08 | 2017-03-08 | Neuroactive steroids, compositions, and uses thereof |
Country Status (19)
Country | Link |
---|---|
US (4) | US20200306265A1 (en) |
EP (1) | EP3426257A4 (en) |
JP (3) | JP6838074B2 (en) |
KR (2) | KR102408399B1 (en) |
CN (2) | CN109414444A (en) |
AU (2) | AU2017229656B2 (en) |
BR (1) | BR112018067998A2 (en) |
CA (2) | CA3017172C (en) |
HK (1) | HK1258616A1 (en) |
IL (2) | IL300422A (en) |
JO (1) | JOP20170059B1 (en) |
MA (1) | MA43815A (en) |
MX (2) | MX2018010902A (en) |
PH (1) | PH12018501923A1 (en) |
RU (2) | RU2022102537A (en) |
SG (1) | SG11201807785VA (en) |
TW (2) | TWI798173B (en) |
WO (1) | WO2017156103A1 (en) |
ZA (1) | ZA201805905B (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108976272B (en) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof |
RU2019104004A (en) | 2012-01-23 | 2019-03-07 | Сейдж Терапьютикс, Инк. | MEDICINAL FORMS OF NEUROACTIVE STEROIDS AND METHODS OF TREATING CNS DISORDERS |
DK2925327T3 (en) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolone for the treatment, reduction or relief of symptoms of postpartum depression |
HUE051403T2 (en) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | 19-nor neuroactive steroids for methods of treatment |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
KR20230172622A (en) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
PT3021852T (en) | 2013-07-19 | 2021-04-21 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
CA2921512A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
HUE051488T2 (en) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
DK3250210T3 (en) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS |
US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
RU2019103590A (en) | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | C17-, C20- AND C21-SUBSTITUTED NEUROACTIVE STEROIDS AND METHODS OF THEIR APPLICATION |
JP2019524853A (en) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス, インコーポレイテッド | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
CN111565724A (en) * | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | Ganaxolone for treating hereditary epilepsy |
US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
MX2020008182A (en) * | 2018-02-11 | 2020-09-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Steroid derivative regulators, method for preparing the same, and uses thereof. |
CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
CA3118688A1 (en) * | 2018-11-05 | 2020-05-14 | Ovid Therapeutics Inc. | Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
CN109503694A (en) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | A kind of novel GABAAReceptor modulators and application thereof |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
KR20210116523A (en) * | 2019-01-14 | 2021-09-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | Tetrazolone Substituted Steroids and Uses Thereof |
US11497754B2 (en) | 2019-02-05 | 2022-11-15 | Washington University | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions |
JP2022534424A (en) | 2019-05-31 | 2022-07-29 | セージ セラピューティクス, インコーポレイテッド | Neuroactive steroids and compositions thereof |
JP2022543837A (en) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ, インコーポレイテッド | Ganaxolone for use in treating status epilepticus |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
JP2023503928A (en) * | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ, インコーポレイテッド | Ganaxolone for use in the treatment of tuberous sclerosis |
MX2022008614A (en) * | 2020-01-12 | 2022-10-10 | Brii Biosciences Inc | Neuroactive steroids and pharmaceutical composition containing the same. |
EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
WO2022125408A1 (en) * | 2020-12-07 | 2022-06-16 | Marinus Pharmaceuticals, Inc | Use of ganaxolone in treating an epilepsy disorder |
CN112516086B (en) * | 2020-12-08 | 2022-05-20 | 武汉久安药物研究院有限公司 | Breynolone fat emulsion for injection and preparation method thereof |
WO2022165017A1 (en) * | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
IL307516A (en) * | 2021-04-12 | 2023-12-01 | Sage Therapeutics Inc | Treatment of essential tremor |
US11337987B1 (en) * | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
KR20240037975A (en) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | Crystalline forms of neuroactive steroids |
WO2023146579A1 (en) * | 2022-01-27 | 2023-08-03 | Belnap Pharmaceuticals, Llc | Methods of treatment using oxytocin |
WO2023164385A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
WO2023211856A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Methods for the treatment of neurological disorders |
US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
WO2024059608A1 (en) * | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
CN115957332B (en) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | Hyaluronidase-stable breinox Long Nami crystal and preparation method and application thereof |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
BE754111A (en) | 1969-07-29 | 1971-01-29 | Upjohn Co | NEW 7ALPHA- AND 7BETA-METHYL-3ALPHA, 5ALPHA- CYCLOANDROSTANES AND SIMILAR 19-NOR COMPOUNDS AND THEIR PREPARATION PROCESS |
US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
SE8600632D0 (en) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | NOVEL PHARMACEUTICAL COMPOSITION |
US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | Novel gaba a? receptor with steroid binding sites. |
AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
JP4066272B2 (en) | 1994-02-14 | 2008-03-26 | ユーロ‐セルティック エス. ア. | Androstanes and pregnanes for allosteric modulation of GABA receptors |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
ATE372966T1 (en) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | IMPROVED EFFECTIVENESS OF DRUGS THROUGH DEUTERATION |
AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
AU707486B2 (en) | 1994-11-23 | 1999-07-08 | Euro-Celtique S.A. | Androstane and pregnane series for allosteric modulation of gaba receptor |
US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
UA57706C2 (en) | 1995-06-06 | 2003-07-15 | Косенсіз, Інк | Neuroactive steroids of the androstane and pregnane series, a method for treatment (variants) |
WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
WO1999045931A1 (en) | 1998-03-11 | 1999-09-16 | Baeckstroem Torbjoern | Epiallopregnanolone in the treatment of cns disorders |
US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
DK1104760T3 (en) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoyl heteroarylpyrazole compounds as anti-inflammatory / analgesic agents |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
GR1003861B (en) | 2000-12-29 | 2002-04-11 | Novel gabaa modulating neurosteroids | |
AU2002250064B2 (en) | 2001-02-13 | 2008-01-17 | University Of Florida Research Foundation, Inc. | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
ATE415155T1 (en) | 2001-05-24 | 2008-12-15 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM, OR TRIAZOLAM BY INHALATION |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
WO2002094244A2 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
JP2003063965A (en) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | Cilostazol aqueous composition for injection |
US20040138187A1 (en) | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
CA2527019A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US7892483B2 (en) | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
WO2006110172A2 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals.Inc. | Steroid analogs and characterization and treatment methods |
JP2008530134A (en) | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate benzodiazepine aerosol and injectable formulations |
DK1868614T3 (en) | 2005-03-24 | 2012-11-12 | Univ Emory | Dose regimen to treat a traumatic brain injury with progesterone |
EP1868593A2 (en) | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
NZ568700A (en) | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
EP2029564A4 (en) * | 2006-05-22 | 2010-01-13 | Vanda Pharmaceuticals Inc | Treatment for depressive disorders |
KR20090064418A (en) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | Combinations containing a 4-acylaminopyridine derivative |
US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
JP2010523708A (en) | 2007-04-11 | 2010-07-15 | バイオマリン ファーマシューティカル インコーポレイテッド | Methods for administering tetrahydrobiopterin, related compositions and methods of measurement |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
US8969329B2 (en) | 2007-06-11 | 2015-03-03 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function |
AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
EP2175886A1 (en) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
JP2011507800A (en) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | AMPA receptor antagonists for epilepsy, mental disorders, or sensory organ disorders |
EP2224927B1 (en) | 2008-01-03 | 2014-08-20 | BioMarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
CZ301216B6 (en) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnane anionic compounds, process for preparing thereof and their use |
HUE033711T2 (en) | 2008-10-10 | 2017-12-28 | Vm Discovery Inc | Compositions and methods for treating alcohol use disorders, pain and other diseases |
EP2376073A2 (en) | 2008-11-30 | 2011-10-19 | Oron Zachar | Dermal application of vasoconstrictors |
EP2376072A1 (en) * | 2008-12-29 | 2011-10-19 | Tartu Ülikool (University Of Tartu) | Arginase inhibitors for the treatment of depression |
WO2010088409A2 (en) | 2009-01-30 | 2010-08-05 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
US20120142645A1 (en) | 2009-03-17 | 2012-06-07 | Marx Christine E | Neuroactive steroid compositions and methods of use for lowering cholesterol |
WO2011079047A1 (en) * | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
NO2525798T3 (en) | 2010-01-21 | 2018-01-06 | ||
DK2635333T3 (en) | 2010-11-03 | 2014-12-08 | Sanofi Aventis Deutschland | Needle containing drug |
US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
CZ201181A3 (en) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Pregnanolone derivatives substituted in position 3alpha with cationic group, process of their preparation, their use and composition containing them |
US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
FR2973031B1 (en) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION |
US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
WO2013002584A2 (en) | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | Combination of effective substances causing synergistic effects of multiple targeting and use thereof |
JP2014521662A (en) * | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Novel 17β-heteroaryl substituted steroids as modulators of GABAA receptors |
CA2848212C (en) * | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
CN108976272B (en) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3, 3-disubstituted 19-norpregnane compounds, compositions, and uses thereof |
US9125926B2 (en) | 2011-11-29 | 2015-09-08 | Amino Up Chemical Co. Ltd | Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent |
RU2019104004A (en) | 2012-01-23 | 2019-03-07 | Сейдж Терапьютикс, Инк. | MEDICINAL FORMS OF NEUROACTIVE STEROIDS AND METHODS OF TREATING CNS DISORDERS |
WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
US20140057885A1 (en) * | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
DK2925327T3 (en) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolone for the treatment, reduction or relief of symptoms of postpartum depression |
ES2680582T3 (en) | 2012-12-18 | 2018-09-10 | Washington University | 19-Alkoxy-17-substituted neuroactive steroids, prodrugs thereof and methods of treatment therewith |
WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
HUE051403T2 (en) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | 19-nor neuroactive steroids for methods of treatment |
KR20230172622A (en) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
PT3021852T (en) | 2013-07-19 | 2021-04-21 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
CA2921512A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
HRP20221294T1 (en) * | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions and uses thereof |
WO2015195962A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JOP20200195A1 (en) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
EP4059522A1 (en) | 2015-02-06 | 2022-09-21 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
JP6957455B2 (en) | 2015-10-14 | 2021-11-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Increased beta cell replication and / or survival |
MA43815A (en) | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
KR20230050474A (en) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | Methods and compositions for treatment of epileptic disorders |
US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
CA3042213A1 (en) | 2016-09-07 | 2018-03-15 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
EP3612186A1 (en) | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
AU2018290348B2 (en) | 2017-06-23 | 2024-04-04 | Ayikoe-Guy MENSAH-NYAGAN | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
EP3642206A4 (en) | 2017-06-23 | 2021-04-07 | The Regents of The University of California | Enhancing gaba's ability to modulate immune responses |
CN111565724A (en) | 2017-11-10 | 2020-08-21 | 马瑞纳斯制药公司 | Ganaxolone for treating hereditary epilepsy |
US20190337975A1 (en) | 2018-05-04 | 2019-11-07 | Acerus Pharmaceuticals Corporation | Neurosteroid derivatives and uses thereof |
WO2020097284A1 (en) | 2018-11-08 | 2020-05-14 | Jindal Vinay K | TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF |
CN113395962A (en) | 2018-11-21 | 2021-09-14 | Certego治疗公司 | Gaboxadol for reducing suicidal risk and rapidly relieving depression |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
BR112021011525A2 (en) | 2018-12-14 | 2021-08-31 | Acerus Biopharma Inc. | TESTOSTERONE ACTIVE ESTER DERIVATIVES, COMPOSITIONS AND USES THEREOF |
-
2017
- 2017-03-08 MA MA043815A patent/MA43815A/en unknown
- 2017-03-08 KR KR1020187028838A patent/KR102408399B1/en active IP Right Grant
- 2017-03-08 CA CA3017172A patent/CA3017172C/en active Active
- 2017-03-08 WO PCT/US2017/021325 patent/WO2017156103A1/en active Application Filing
- 2017-03-08 RU RU2022102537A patent/RU2022102537A/en unknown
- 2017-03-08 KR KR1020227019157A patent/KR20220084418A/en not_active Application Discontinuation
- 2017-03-08 MX MX2018010902A patent/MX2018010902A/en unknown
- 2017-03-08 CN CN201780027222.4A patent/CN109414444A/en active Pending
- 2017-03-08 SG SG11201807785VA patent/SG11201807785VA/en unknown
- 2017-03-08 US US16/083,339 patent/US20200306265A1/en not_active Abandoned
- 2017-03-08 JP JP2018546817A patent/JP6838074B2/en active Active
- 2017-03-08 CA CA3158448A patent/CA3158448A1/en active Pending
- 2017-03-08 RU RU2018135079A patent/RU2766155C2/en active
- 2017-03-08 IL IL300422A patent/IL300422A/en unknown
- 2017-03-08 BR BR112018067998-4A patent/BR112018067998A2/en not_active Application Discontinuation
- 2017-03-08 CN CN202110912361.3A patent/CN113616661A/en active Pending
- 2017-03-08 AU AU2017229656A patent/AU2017229656B2/en active Active
- 2017-03-08 TW TW106107640A patent/TWI798173B/en active
- 2017-03-08 TW TW112108775A patent/TW202400182A/en unknown
- 2017-03-08 EP EP17763984.6A patent/EP3426257A4/en active Pending
- 2017-03-08 JO JOP/2017/0059A patent/JOP20170059B1/en active
-
2018
- 2018-09-03 ZA ZA2018/05905A patent/ZA201805905B/en unknown
- 2018-09-06 IL IL261658A patent/IL261658B2/en unknown
- 2018-09-07 PH PH12018501923A patent/PH12018501923A1/en unknown
- 2018-09-07 MX MX2022003896A patent/MX2022003896A/en unknown
-
2019
- 2019-01-18 HK HK19100976.7A patent/HK1258616A1/en unknown
- 2019-12-18 US US16/718,430 patent/US10940156B2/en active Active
-
2021
- 2021-02-10 JP JP2021019539A patent/JP2021073309A/en active Pending
- 2021-03-08 US US17/195,129 patent/US11554125B2/en active Active
-
2022
- 2022-12-08 US US18/077,279 patent/US20230355639A1/en active Pending
- 2022-12-09 AU AU2022283769A patent/AU2022283769A1/en active Pending
-
2023
- 2023-04-28 JP JP2023074398A patent/JP2023093723A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201908090VA (en) | Biomonitoring devices, methods, and systems for use in a bathroom setting | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201908790PA (en) | Glucocorticoid receptor modulators to treat cervical cancer | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis |